Document is current
Any future updates will be listed below
-
Authors
Moreno, Alberto https://orcid.org/0000-0002-3031-7194
Manning, Kelly https://orcid.org/0000-0002-6262-1190
Azeem, Maryam I.
Nooka, Ajay K.
Ellis, Madison https://orcid.org/0000-0002-0325-5477
Manalo, Renee Julia
Switchenko, Jeffrey M.
Wali, Bushra
Kaufman, Jonathan L.
Hofmeister, Craig C. https://orcid.org/0000-0003-4816-1607
Joseph, Nisha S.
Lonial, Sagar
Dhodapkar, Kavita M. https://orcid.org/0000-0003-0587-4172
Dhodapkar, Madhav V. https://orcid.org/0000-0002-8249-5988
Suthar, Mehul S.
- License Information
-
More Information
Article History
Received: 24 August 2023
Accepted: 17 October 2024
First Online: 27 October 2024
Competing interests
: A.M. reports grants from NIH during the conduct of the study. J.L.K. reports grants from NIH during the conduct of the study and personal fees from AbbVie, BMS, Janssen, and Incyte outside the submitted work. S.L. reports personal fees from Amgen, grants and personal fees from Takeda, Janssen, and BMS, personal fees from Pfizer, Genentech, AbbVie, and Celgene outside the submitted work; and Board of Directors TG Therapeutics with stock. M.V.D. personal fees from Sanofi, BMS, and Lava Therapeutics outside the submitted work. M.S.S. reports grants and personal fees from Moderna and Ocugen outside the submitted work. No disclosures were reported by the other authors.
